Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
48.85 USD | +1.60% | -10.63% | +1.92% |
May. 15 | HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating | MT |
May. 14 | Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer | MT |
Valuation
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 383.3 | 453 | - | - |
Enterprise Value (EV) 1 | 383.3 | 453 | 453 | 453 |
P/E ratio | -0.9 x | -5.07 x | -5.18 x | -5.92 x |
Yield | - | - | - | - |
Capitalization / Revenue | - | - | - | - |
EV / Revenue | - | - | - | - |
EV / EBITDA | - | - | - | - |
EV / FCF | -5.1 x | -5.18 x | -4.77 x | -4.27 x |
FCF Yield | -19.6% | -19.3% | -21% | -23.4% |
Price to Book | - | - | - | - |
Nbr of stocks (in thousands) | 7,997 | 9,273 | - | - |
Reference price 2 | 47.93 | 48.85 | 48.85 | 48.85 |
Announcement Date | 3/26/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | - | -84.53 | -86.3 | -95.42 | -101.8 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -58.02 | -81.14 | -81.12 | -92.65 | -101.8 |
Net income 1 | -58.03 | -81.17 | -81.16 | -92.65 | -101.8 |
Net margin | - | - | - | - | - |
EPS 2 | - | -53.08 | -9.640 | -9.437 | -8.250 |
Free Cash Flow 1 | - | -75.12 | -87.5 | -95 | -106 |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 7/27/23 | 3/26/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | -26.89 | -21.45 | -20.91 | -21.28 | -21.91 | -22.5 | -23.12 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -25.4 | -19.54 | -20.33 | -20.51 | -21.22 | -21.88 | -22.6 |
Net income 1 | -25.43 | -19.56 | -20.34 | -20.51 | -21.22 | -21.88 | -22.6 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | -43.10 | -2.440 | -2.395 | -2.340 | -2.465 | -2.600 | -2.480 |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 3/26/24 | 5/14/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt | - | - | - | - | - |
Net Cash position | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow 1 | - | -75.1 | -87.5 | -95 | -106 |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex 1 | - | 7.84 | 5 | 5 | - |
Capex / Sales | - | - | - | - | - |
Announcement Date | 7/27/23 | 3/26/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.92% | 453M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.98% | 40.65B | |
-10.87% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- KRRO Stock
- Financials Korro Bio, Inc.